Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 20 studies | 59% ± 16% | |
lung | 19 studies | 63% ± 19% | |
brain | 17 studies | 38% ± 14% | |
intestine | 14 studies | 48% ± 24% | |
eye | 10 studies | 57% ± 20% | |
kidney | 9 studies | 66% ± 13% | |
lymph node | 6 studies | 61% ± 17% | |
liver | 6 studies | 55% ± 21% | |
pancreas | 5 studies | 72% ± 21% | |
bone marrow | 5 studies | 43% ± 12% | |
placenta | 5 studies | 62% ± 28% | |
uterus | 5 studies | 74% ± 18% | |
prostate | 4 studies | 67% ± 24% | |
breast | 4 studies | 74% ± 8% | |
heart | 3 studies | 41% ± 14% | |
adipose | 3 studies | 33% ± 18% | |
adrenal gland | 3 studies | 59% ± 5% | |
esophagus | 3 studies | 65% ± 23% | |
skin | 3 studies | 60% ± 14% | |
thymus | 3 studies | 77% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 21186.70 | 2642 / 2642 | 100% | 74.13 | 705 / 705 |
esophagus | 100% | 14955.41 | 1445 / 1445 | 100% | 30.64 | 183 / 183 |
ovary | 100% | 16508.46 | 180 / 180 | 100% | 37.65 | 430 / 430 |
prostate | 100% | 15076.20 | 245 / 245 | 100% | 50.38 | 502 / 502 |
uterus | 100% | 15534.85 | 170 / 170 | 100% | 38.51 | 459 / 459 |
breast | 100% | 15429.46 | 459 / 459 | 100% | 60.63 | 1117 / 1118 |
thymus | 100% | 16482.96 | 653 / 653 | 100% | 61.00 | 604 / 605 |
intestine | 100% | 15091.37 | 966 / 966 | 100% | 34.27 | 526 / 527 |
lung | 100% | 12176.84 | 576 / 578 | 100% | 35.43 | 1155 / 1155 |
stomach | 100% | 10561.35 | 359 / 359 | 100% | 30.55 | 285 / 286 |
adrenal gland | 100% | 17909.19 | 258 / 258 | 100% | 59.11 | 229 / 230 |
kidney | 100% | 16739.47 | 89 / 89 | 100% | 43.81 | 897 / 901 |
bladder | 100% | 15226.00 | 21 / 21 | 99% | 36.66 | 501 / 504 |
skin | 100% | 14341.26 | 1809 / 1809 | 99% | 35.60 | 468 / 472 |
liver | 98% | 6190.25 | 222 / 226 | 100% | 30.15 | 406 / 406 |
pancreas | 95% | 5159.69 | 313 / 328 | 99% | 36.00 | 177 / 178 |
adipose | 100% | 14004.08 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 22045.95 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 34.57 | 29 / 29 |
muscle | 100% | 19582.42 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 10390.56 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 31.79 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.94 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 98% | 29.21 | 78 / 80 |
heart | 97% | 14062.97 | 832 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 7042.50 | 869 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0006338 | Biological process | chromatin remodeling |
GO_1904668 | Biological process | positive regulation of ubiquitin protein ligase activity |
GO_0051457 | Biological process | maintenance of protein location in nucleus |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0006513 | Biological process | protein monoubiquitination |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0031519 | Cellular component | PcG protein complex |
GO_0005813 | Cellular component | centrosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0031467 | Cellular component | Cul7-RING ubiquitin ligase complex |
GO_0005634 | Cellular component | nucleus |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0140677 | Molecular function | molecular function activator activity |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0160072 | Molecular function | ubiquitin ligase complex scaffold activity |
GO_0097602 | Molecular function | cullin family protein binding |
GO_0008013 | Molecular function | beta-catenin binding |
GO_1990444 | Molecular function | F-box domain binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SKP1 |
Protein name | S-phase kinase-associated protein 1 (Cyclin-A/CDK2-associated protein p19) (p19A) (Organ of Corti protein 2) (OCP-2) (Organ of Corti protein II) (OCP-II) (RNA polymerase II elongation factor-like protein) (SIII) (Transcription elongation factor B polypeptide 1-like) (p19skp1) S-phase kinase-associated protein 1 S-phase kinase-associated protein 1 (Cyclin-A/CDK2-associated protein p19) (p19skp1) S-phase kinase associated protein 1 |
Synonyms | SKP1A OCP2 TCEB1L EMC19 |
Description | FUNCTION: Essential component of the SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complex, which mediates the ubiquitination of proteins involved in cell cycle progression, signal transduction and transcription. In the SCF complex, serves as an adapter that links the F-box protein to CUL1. The functional specificity of the SCF complex depends on the F-box protein as substrate recognition component. SCF(BTRC) and SCF(FBXW11) direct ubiquitination of CTNNB1 and participate in Wnt signaling. SCF(FBXW11) directs ubiquitination of phosphorylated NFKBIA. SCF(BTRC) directs ubiquitination of NFKBIB, NFKBIE, ATF4, SMAD3, SMAD4, CDC25A, FBXO5, CEP68 and probably NFKB2 . SCF(SKP2) directs ubiquitination of phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition. SCF(SKP2) directs ubiquitination of ORC1, CDT1, RBL2, ELF4, CDKN1A, RAG2, FOXO1A, and probably MYC and TAL1. SCF(FBXW7) directs ubiquitination of cyclin E, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. SCF(FBXW2) directs ubiquitination of GCM1. SCF(FBXO32) directs ubiquitination of MYOD1. SCF(FBXO7) directs ubiquitination of BIRC2 and DLGAP5. SCF(FBXO33) directs ubiquitination of YBX1. SCF(FBXO11) directs ubiquitination of BCL6 and DTL but does not seem to direct ubiquitination of TP53. SCF(BTRC) mediates the ubiquitination of NFKBIA at 'Lys-21' and 'Lys-22'; the degradation frees the associated NFKB1-RELA dimer to translocate into the nucleus and to activate transcription. SCF(CCNF) directs ubiquitination of CCP110. SCF(FBXL3) and SCF(FBXL21) direct ubiquitination of CRY1 and CRY2. SCF(FBXO9) directs ubiquitination of TTI1 and TELO2. SCF(FBXO10) directs ubiquitination of BCL2. . FUNCTION: Essential component of the SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complex, which mediates the ubiquitination of proteins involved in cell cycle progression, signal transduction and transcription. In the SCF complex, serves as an adapter that links the F-box protein to CUL1. .; FUNCTION: The functional specificity of the SCF complex depends on the F-box protein as substrate recognition component. . |
Accessions | F8W8N3 ENST00000522855.5 [P63208-1] ENST00000522552.5 [P63208-2] ENST00000521216.5 ENST00000523966.5 P63208 E7ERH2 E5RHM3 ENST00000523359.1 ENST00000519321.5 ENST00000519054.5 ENST00000517625.5 [P63208-1] ENST00000520417.1 E5RGM4 ENST00000328392.10 E5RK33 E5RJR5 ENST00000353411.11 [P63208-1] E5RGM3 |